Drugs / AVTX-803
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05754450 | Apr 2023 → Dec 2026 expected | leukocyte adhesion deficiency | AUG Therapeutics | Recruiting | No outcome recorded |
| Phase 3 | NCT05462587 | Jul 2022 → Nov 2026 expected | leukocyte adhesion deficiency | AUG Therapeutics | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-08-02 | Avalo Therapeutics, Inc. | Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II) August 02, 2022 7:30am EDT avalotx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVTX-803 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05754450 ↗ |
| Known as | L-Fucose | “AVTX-803 (L-Fucose)” NCT05462587 ↗ |